DAFTAR PUSTAKA

Abdou, H.M. (1989). Dissolution, Bioavailability and Bioequivalence.

Pennsylvania: Mack Printing Company.

Amidon GL, Lennrnas H, Shah Vp, Crison Jr et al. (1995). A theoretical

basis for a biopharmacetic drug classification : the correlation of in
vitrodrug product dissolution and in vivo bioavaibility. Pharm.
Res. 12 (3), 413-20

Anief, M. 1997, Apa yang Perlu Diketahui Obat, Yogyakarta: Gadjah

Mada University Press.

Ansel, H.C.,Allen, L.V.Jr.and Popovich, N.G. 2005.Pharmaceutical

Dosage Form and Drug Delivery System, 7 th ed.USA: Lippincot
Williams and Wilkins.

Ardiarini, A. 2006. Perbandingan Bioavaibbilitas (Bioekivalensi) Obat

Cimetidine dalam Sediaan Generik dan Paten Secara In
Vitro. Skripsi. Semarang : Fakultas Kedokteran Universitas
Diponegoro.

Badan POM RI.2015.Pusat Informasi Obat Nasional.http://pionas.pom.go.

id/monografi/ irbesartan

Badan POM RI. 2004. Pedoman Uji Bioekivalensi. Jakarta: Badan

Pengawasan Obat dan Makanan Republik Indonesia.

Badan POM RI. 2011. Obat Wajib Bioekivalensi. Jakarta: Badan

Pengawasan Obat dan Makanan Republik Indonesia.

Banakar, U.V. 1992. Pharmaceutical Dissolution Testing. New York :

Marcel Dekker, Inc.

Banjare, L., Chandra J. K, Patel P. (2013). Method Development and

Validation For Estimation of Irbesartan In Bulk Drug and
Pharmaceutical. Journal of Drug Delivery and Therapetutics. 3(6),
87-90.

Basset, J., Denney, R. C., Jeffrey, G. H., dan Mendham, J. 1994. Kimia
Analisis Kuantitatif Anorganik. Jakarta: Buku Kedokteran-EGC.

Dash, S., Murthy, P.N., Nath, L., Chowdhury, P. (2010). Kinetic Modeling
on Drug Release from Controlled Drug Delivery System. Acta
Poloniae Pharmaceutics-Drug Research, 67 (3), 217-223.
Departemen Kesehatan Republik Indonesia. 1995. Farmakope Indonesia,
edisi keempat. Jakarta: Depkes RI.

Departemen Kesehatan Republik Indonesia. 2014. Farmakope Indonesia

edisi kelima.Jakarta: Depkes RI.

Departemen Kesehatan. Permenkes RI nomor HK.02.02/ MENKES/ 068 /I/

2010.

Dressman, J., and Butler, J.2001.The Biopharmaceutical Classification

System, (http://www. Pharmaportal.com), diakses 3Mei 2016.

Gerald K. McEvoy. 2011. AHFS Drug Information Essential. American

Society of Health System Pharmacists® : Bethesda, Maryland.

Gu Shifen, Chen Hui, Qiu Y., Shi S., dan Zeng. (2002). Study on the
Pharmacokinetics and Relative Bioavaibility of Irbesartan Capsules
in Healthy Volunteers. Journal of Huazhang University of Science
and Technology : 22 (1), 14-16

Harjadi, W. 1993. Ilmu Kimia Analitik Dasar. Jakarta : PT Gramedia

Pustaka Utama.

Hirlekar. R and Kadam V. (2009). Preformulation Study of the Inclusion

Complex Irbesartan β Cyclodextrin. AAPS Pharm Sci Tech. 10(1)

James W.M. 1991. Analisis Farmasi. Surabaya: Airlangga University Press

Khopkar, S.M. 2003. Kimia Analitis. Jakarta: UI Press

Koester, L. S. Ortega, G.G. Mayorga, P. dan Bassani, V. L. (2004).

Mathematical Evaluation of In Vitro Release Profile of HPMC
Matrix Tabltes Containing Carbamazepim Associated to ß
Cyclodextrin. European Journal of Pharmaceutics and
Biopharmaceutics (EJPB). 58 (1) :177-179

Kumar. G.A, Choudary.R.K dan Chaitanya. CH . 2011. Enhancement of

Solubility and Dissolution Rate of Irbesartan by Solid dspersion
Technique. Asian Journal of Pharmaceutical and Clinical Reseach
4 (2).

Lachman L., Lieberman, H.A., dan Kanig, J.L. 1994. Teori dan Praktek
Farmasi Industri II. Edisi Ketiga. Jakarta : UI Press.

Lachman,L., Lieberman, H.H., and Kanig, J. L.1986.The Theory and

Practice of Industrial Pharmacy.2nded.Philadelpia : Leaand Febigeer
Martin A,SwarbickJ,CammarataA. 1993. Farmasi Fisik ; Dasar-Dasar
Farmasi Fisik Dalam Ilmu Farmasetik. Jakarta : UI Press

Martindale 35. 2007. The Complete Drug Reference. London:

Pharmaceutical Press
Meka. A. K., Pola. S., Tupally. K.R., Abbaraju. P. L. (2012). Development
Evaluation and Characterization of survace solid dispersion for
solubility and dissolution enhancementof Irbesartan. IJDDR. 4 (1).

Mouzam, I., Dehghan, M. H. G., Asif, S., Sahuji, T., Chudiwal, P. (2011).
Development of a Novel Floating Ring Capsule-Type Dosage Form
for Stomach Spesific Delivery. Saudi Pharmaceutical Journal.

Mulye, N.V., & Turco, S,J. (1995). A Simple Model Based on First Order
Kinetics to Explain Release of Highly Water Soluble Drugs Form
Porous Dicalciumphosphate dyhidrate Matrices. Drug Dev. Ind.
Pharm, 21, 843-953.

Nugraheni, D. 2006. Perbandingan Bioavaibilitas Alopurinol dalam

Sediaan Generik dan Paten Secara in Vitro. Semarang: Fakultas
Kedokteran Universitas Diponegoro.

Nurtanti M.P, Kusuma A.M, Siswanto A. (2010). Profil Disolusi

Terbanding Tablet Rifampisin Merek dan Generik. Pharmacy.7
(10).

Parrot, E. 1970. Pharmaceutical Technology Fundamental Pharmaceutics.

United States of America: Burgess Publishing Company.

Peraturan Menteri Kesehatan Nomor 085/Menkes/ Per/1/1989 tentang

Kewajiban Menuliskan dan/atau Menggunakan Obat Generik di
Fasilitas Pelayanan Kesehatan Pemerintah

Ramadhana, B. 2005.Analisis disolusi dan Waktu Hancur Tablet Salut dan

Non Salut Asam Mefenamat 500 mg. Tugas Akhir. Bogor : Akademi
Kimia Analisa.

Reza, MD Selim, M.A. Quadir, S.sS. Haider. (2003). Comparative

Evaluation of Plastic, Hydrofobic, and Hydrofilic Polymers as
Matrices for Controlled-Release Drug Delivery. J. Of Pharm.
Sci.6(2): 274-291

S Udin dan D Hedi R. 2003. Histamin dan Antialergi dalam Farmakologi

dan Terapi. Edisi IV. Jakarta: Bagian Farmakologi Universitas
Indonesia
Sari. D.P., Sulaiman. T. N., Mafruhah.O.R, 2013. Uji disolusi Terbanding
Tablet Metformin hidroklorida Generik Berlogo dan Bermerek.
Majalah Farmasuetik. 9.

Shah V.P., etal. 1999. Dissolution profile comparison using similarity

factor, f2, Dissolution Technologies. 6(3), 21.

Shargel, L. And andrew B. C. YU. 2005. Applied Biopharmacetics and

Phaemacokinetics. USA: Appeton and Lange

Shete A.S., Yadav A.V., dan Murthy M.S. (2012). Enhancement of

Dissolution Rate of Irbesartanby Chitosan based Crystal
Enginering Technique. Indian Journal of Pharmaceutical
Education and Research. 6 (4).

Siepmann, J. and Peppas, N.A. (2001). Modelling of Drug release from

Delivery systems based HPMC. Adv. Drug Delivery Reviews. 48,
139 157.

Stoklosa MJ, Ansel HC.1991. Pharmaceutical Calcutations 9th. London:

Lea & Febiger.

Sulaiman, T. N. S. 2007. Teknologi dan Formulasi Sediaan

Tablet.Yogyakarta : Pustaka Laboratorium Teknologi Farmasi,
Fakultas Farmasi,Universitas Gadjah Mada.

Sumantomo B. 2006. Perbandingan Bioavailabilitas Pirazinamid Dalam

Sediaan Generik Dan Paten Secara In Vitro.Artikel Karya Tulis
Ilmiah.Semarang :Universitas Diponegoro.

Sweetman, S.C. 2009. Martindale, The Complete Drug Reference 36th ed.
London: The Pharmaceutical Press.

Syukri, Y. 2002. Biofarmasetika. Jakarta : UI Press

Tatro David S. 2013. A to Z drug Facts. Facts and Comparisons

Voight, R. 1994. Buku Pelajaran teknologi Farmasi, Edisi Kelima.
Yogyakarta: Gadjah Mada University Press.
Wagner, J. G. 1971.Biopharmaceutical and Relevant Pharmacokinetics,
1th ed, 2-5, 98-100. DNG Intelegence Publication Hamilton. Illionis.

Wicaksono, Y., Hendradi, E., & Radjaram, A. 2005. Analisis Proses Lepas
Lambat Na diklofenak dari Tablet Matrik Berbasis Etilselulosa
Polivinilpirolidon K-30. Seminar Nasional MIPA.
Widodo, R. 2004. Panduan Keluarga memilih dan menggunakan
Obat.Yogyakarta: Kreasi wacana

Yuksel N., Kanık Arzu E., Baykara T., 2000. Comparison of in vitro
dissolution profiles by ANOVA-based, model-dependent and
independent methods. International Journal of Pharmaceutics. 209
57-67